Profile data is unavailable for this security.
About the company
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.
- Revenue in USD (TTM)0.00
- Net income in USD-16.58m
- Incorporated2014
- Employees8.00
- LocationNeuroBo Pharmaceuticals Inc545 Concord Avenue, Suite 210CAMBRIDGE 02138United StatesUSA
- Phone+1 (857) 702-9600
- Fax+1 (734) 293-0444
- Websitehttps://www.neurobopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cocrystal Pharma Inc | 0.00 | -16.75m | 23.40m | 12.00 | -- | 1.04 | -- | -- | -1.65 | -1.65 | 0.00 | 2.22 | 0.00 | -- | -- | 0.00 | -52.03 | -50.94 | -56.92 | -52.77 | -- | -- | -- | -1,501.78 | -- | -- | 0.00 | -- | -- | -- | 53.69 | -- | 33.34 | -- |
| Hcw Biologics Inc | 3.93m | -27.39m | 23.45m | 45.00 | -- | 2.68 | -- | 5.97 | -0.7547 | -0.7547 | 0.1083 | 0.2311 | 0.1062 | -- | 6.79 | 87,258.22 | -74.07 | -- | -97.78 | -- | 29.61 | -- | -697.59 | -- | -- | -146.89 | 0.4863 | -- | -57.72 | -- | -67.74 | -- | -- | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.88m | 23.81m | 16.00 | -- | -- | -- | -- | -0.7299 | -0.7299 | 0.00 | -0.4488 | 0.00 | -- | -- | 0.00 | -350.36 | -- | -5,244.59 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 18.10 | -- | -- | -- |
| Biomx Inc | 0.00 | -37.14m | 23.91m | 58.00 | -- | -- | -- | -- | -0.6234 | -0.6234 | 0.00 | 0.3813 | 0.00 | -- | -- | 0.00 | -60.38 | -- | -72.74 | -- | -- | -- | -- | -- | -- | -2.25 | 0.00 | -- | -- | -- | 7.59 | -- | -- | -- |
| Yubo International Biotech Ltd | 455.72k | -1.26m | 23.98m | 18.00 | -- | -- | -- | 52.61 | -0.0105 | -0.0105 | 0.0038 | -0.0172 | 0.2488 | 0.4126 | 5.27 | 25,317.78 | -70.32 | -- | -- | -- | 80.24 | -- | -282.61 | -- | 0.1487 | -4,023.75 | -- | -- | 479.86 | -- | 0.8224 | -- | -- | -- |
| Janone Inc | 0.00 | -18.58m | 24.16m | 5.00 | -- | -- | -- | -- | -3.66 | -3.95 | 0.00 | 1.01 | 0.00 | -- | -- | 0.00 | -69.38 | -23.12 | -88.46 | -62.22 | -- | 23.38 | -- | -30.14 | -- | -- | 0.1264 | -- | -- | -- | -313.15 | -- | -- | -- |
| Sol Gel Technologies Ltd | 1.72m | -22.86m | 25.07m | 36.00 | -- | 0.7679 | -- | 14.58 | -0.8222 | -0.8222 | 0.0619 | 1.17 | 0.0387 | -- | 0.5154 | 47,777.78 | -51.40 | -31.60 | -57.29 | -35.49 | -- | -- | -1,329.13 | -135.76 | -- | -- | 0.00 | -- | -59.98 | 64.50 | -82.52 | -- | -33.78 | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 25.34m | 8.00 | -- | 2.18 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| BioVie Inc | 0.00 | -37.18m | 25.43m | 18.00 | -- | 1.34 | -- | -- | -0.9626 | -0.9626 | 0.00 | 0.3104 | 0.00 | -- | -- | 0.00 | -94.32 | -456.35 | -149.75 | -1,810.88 | -- | -- | -- | -- | -- | -- | 0.2969 | -- | -- | -- | -92.67 | -- | -- | -- |
| Dare Bioscience Inc | 2.82m | -28.87m | 26.03m | 23.00 | -- | -- | -- | 9.24 | -3.81 | -3.81 | 0.37 | -1.31 | 0.1299 | -- | 1.49 | 122,486.50 | -133.12 | -109.51 | -4,386.38 | -246.26 | 0.0579 | -- | -1,024.93 | -1,104.55 | -- | -- | -- | -- | -71.92 | -- | 2.54 | -- | 121.37 | -- |
| Correlate Energy Corp | 7.95m | -13.85m | 26.08m | 19.00 | -- | -- | -- | 3.28 | -0.3747 | -0.3747 | 0.2157 | -0.145 | 2.76 | -- | 26.10 | 418,160.50 | -481.76 | -315.47 | -- | -- | 17.98 | 15.42 | -174.38 | -201.03 | -- | -1.07 | -- | -- | 122.20 | 46.12 | -78.54 | -- | -- | -- |
| RenovoRx Inc | 0.00 | -8.05m | 26.83m | 8.00 | -- | 10.69 | -- | -- | -0.7249 | -0.7249 | 0.00 | 0.1048 | 0.00 | -- | -- | 0.00 | -172.23 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -3.47 | -- | -- | -- |
| SAB Biotherapeutics Inc | 2.60m | -39.87m | 27.04m | 57.00 | -- | 0.5119 | -- | 10.39 | -6.26 | -6.26 | 0.396 | 5.72 | 0.0456 | -- | 5.44 | 45,657.37 | -69.91 | -- | -86.60 | -- | -- | -- | -1,531.84 | -- | -- | -- | 0.0762 | -- | -90.63 | -- | -125.14 | -- | -- | -- |
| Brainstorm Cell Therapeutics Inc | 0.00 | -15.53m | 27.25m | 29.00 | -- | -- | -- | -- | -0.3227 | -0.3227 | 0.00 | -0.0811 | 0.00 | -- | -- | 0.00 | -276.90 | -117.19 | -- | -231.65 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.18 | -- | -45.34 | -- |
| Alterola Biotech Inc | 0.00 | -2.88m | 27.31m | 1.00 | -- | -- | -- | -- | -0.0027 | -0.0027 | 0.00 | -0.001 | 0.00 | -- | -- | 0.00 | -47.24 | -- | -63.88 | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | -- | -- | 73.07 | -- | -- | -- |
Data as of Jul 03 2024. Currency figures normalised to NeuroBo Pharmaceuticals Inc's reporting currency: US Dollar USD
1.34%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Next Edge Capital Corp.as of 31 Dec 2023 | 36.20k | 0.36% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 28.02k | 0.28% |
| Geode Capital Management LLCas of 31 Mar 2024 | 20.70k | 0.21% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 15.63k | 0.16% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 2024 | 13.51k | 0.14% |
| G1 Execution Services LLCas of 31 Mar 2024 | 12.52k | 0.13% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 5.27k | 0.05% |
| Tower Research Capital LLCas of 31 Mar 2024 | 1.65k | 0.02% |
| Wells Fargo Bank, NA (Private Banking)as of 31 Mar 2024 | 25.00 | 0.00% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Mar 2024 | 25.00 | 0.00% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
